Related Experiment Video
Updated: Feb 4, 2026
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Impaired Blood Rheology in Pulmonary Arterial Hypertension
Yalin Tolga Yaylali1, Emine Kilic-Toprak2, Yasin Ozdemir2
1Pamukkale University, Faculty of Medicine, Department of Cardiology, Denizli, Turkey.
Background:
Understanding of the pathophysiologic manifestations of pulmonary arterial hypertension (PAH) is still evolving. The aims of the present study were to determine the alterations in blood rheology, and to investigate the relationship between those alterations and laboratory parameters in PAH.
Methods:
The study included 21 consecutive treatment-naive patients with PAH and 32 age and sex-matched healthy controls. Patients were categorised in class II (n=6), class III (n=13), and class IV (n=2). All subjects underwent right-heart catheterisation. Erythrocyte deformability and aggregation were measured by an ektacytometer.
Results:
Haemodynamic variables were as follows: the mean right atrial pressure: 9.94±5.76mmHg; the average pulmonary vascular resistance: 5.66±3 WU; Fick cardiac index: 4.15±2.75l/min/m2; and mixed venous O2 saturation: 64.59±12.53%. The average 6-minute walk distance was 351.09±133.08m. Erythrocyte deformability measured at 0.95, 3.00, and 5.33Pa was significantly lower, erythrocyte aggregation index (AI) was higher, and aggregation half-time (t1/2) was lower in PAH. AI and fibrinogen were positively correlated with NT pro-BNP (AI-NT pro-BNP: r=0.579; fibrinogen-NT pro-BNP: r=0.591). t1/2 was negatively correlated with NT pro-BNP (t1/2-NT pro-BNP: r=-0.648).
Conclusions:
The increase in erythrocyte aggregation and the decrease in deformability may theoretically increase the flow resistance and may be of haemodynamic significance. The association between erythrocyte aggregation and NT pro-BNP may indicate that erythrocyte aggregation increases with disease progression. These alterations contribute to the understanding of the pathophysiology and could serve as markers of disease presence.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...